However, ongoing studies using BH3 profiling, a novel ex-vivo functional technique for determining a cancer cell’s reliance on anti-apoptotic proteins, revealed that MM is a diverse disease in terms of anti-apoptotic protein dependency and cannot be considered exclusively BCL2, BCLXL, or MCL1 dependent (59, 60, 83). This evidence concerns the gene BCL2L1 and Miyoshi myopathy.